Denmark
-
Novartis to acquire UK’s Myricx Bio in US$1.5B deal to strengthen next-generation cancer drug pipeline
Founded in 2019 as a spinout from Imperial College London and the Francis Crick Institute, Myricx has attracted strong investor backing and has emerged as one of the UK’s leading oncology biotechnology companies.
-
QuantumCell inks US$2.2B Alzheimer’s deal with AlzeCure Pharma
Under the agreement, QuantumCell will obtain global rights to AlzeCure’s NeuroRestore platform, including its lead drug candidate, ACD856.
-
Novartis inks US$1.9B precision Oncology deal with Antares Therapeutics to target undruggable cancers
Antares will lead the research phase and apply its proprietary drug-discovery platform to a limited number of oncology targets before Novartis decides whether to exercise licensing options for individual programmes.
-
EMA panel recommends approval for Novo Nordisk’s new Wegovy 7.2 mg single-dose pen
Wegovy® 7.2 mg is already available in the European Union for adults with obesity through three separate 2.4 mg injections administered weekly.
-
Novo Nordisk to present new Semaglutide MASH data from ESSENCE trial at EASL 2026
The company’s presentations at EASL 2026 build on results from the Phase 3 ESSENCE programme, where semaglutide 2.4 mg previously demonstrated significant reductions in liver inflammation and fibrosis among patients with MASH.
-
Novo Nordisk oral semaglutide shows superior glycemic control in teens
The study showed that oral semaglutide achieved a significantly greater reduction in HbA1c levels, a key marker of blood sugar control, compared to placebo.
-
Novartis acquires Excellergy for USD2B to develop next-generation allergy treatments
The acquisition signals Novartis’s confidence that Exl-111 can outperform this proven therapy by taking an entirely different approach.
-
Denmark secures historic WHO certification for HIV and syphilis elimination
WHO’s Regional Validation Committee assessed Denmark in June 2025, followed by the Global Validation Advisory Committee in August 2025.
-
Novo Nordisk collaborates with Vivtex to develop oral biologic medicines for obesity
The agreement grants Novo Nordisk licensing rights to select oral drug-delivery technologies from Vivtex.
-
Novartis gains FDA approval for Itvisma gene therapy to treat spinal muscular atrophy
Itvisma works by delivering a functional copy of the survival motor neuron 1 (SMN1) gene through a single, fixed-dose intrathecal injection.